Company: INTS
Filing Date: 2025-04-25
Form Type: 424B4
Source: 0001628280-25-020056
Chunk: 19

Company: INTENSITY THERAPEUTICS, INC.
Filing Date: 2025-04-25
Form: 424B4
Chunk 19
---
 the Securities Act covering the issuance of the underlying shares.

The amounts and timing of any expenditures will vary depending on the amount of cash generated by our operations, and the rate of growth, if any, of our business, and our plans and business conditions. The foregoing represents our intentions as of the date of this prospectus based upon our current plans and business conditions to use and allocate the net proceeds of the offering. However, our management will have significant flexibility and discretion in the timing and application of the net proceeds of the offering. Unforeseen events or changed business conditions may result in application of the proceeds of the offering in a manner other than as described in this prospectus.

To the extent that the net proceeds we receive from the offering are not immediately applied for the above purposes, we plan to invest the net proceeds in short-term, investment-grade, interest-bearing instruments and U.S. government securities.

<div align='center'>12</div>

### MARKET FOR COMMON STOCK AND DIVIDEND POLICY
Our Common Stock is traded on Nasdaq under the symbol “INTS.” The last reported sale price of our Common Stock on April 24, 2025 on the Nasdaq Capital Market was $0.90 per share. As of April 21, 2025, there were 95 stockholders of record of our Common Stock.

We have never declared or paid any cash dividends on our Common Stock and we do not currently intend to pay any cash dividends on the Common Stock in the foreseeable future. We expect to retain all available funds and future earnings, if any, to fund the development and growth of our business. Any future determination to pay dividends, if any, on our Common Stock will be at the discretion of our board of directors and will depend on, among other factors, the terms of any outstanding preferred stock, our results of operations, financial condition, capital requirements and contractual restrictions.

<div align='center'>13</div>

### CAPITALIZATION
The following table sets forth our capitalization as December 31, 2024:

• on an actual basis; and

• on an as adjusted basis, after giving effect to the sale of 3,133,333 shares of our Common Stock in this offering based on a public offering price of $0.75 per share and accompanying Common Warrants, and after deducting Placement Agents’ fees and estimated offering expenses payable by us and assuming no exercise of the Common Warrants issued in connection with this offering.

You should read this table together with our financial statements and the